Englander Institute for Precision Medicine

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. 

An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. 

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

A small subset of T cells, called stem T cells, are responsible for making new T cells and for continuously replenishing them in chronic disease, according to a team of scientists from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.

Dr. Dan Landau has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. 

More than 100 students from across Cornell campuses and 17 other universities gathered in New York City March 6–8 for the Cornell Health AI Hackathon.

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine. 

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. 

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.

Dr. George Coukos, an internationally renowned expert on cancer immunology, is launching the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine.

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Dr. Ekta Khurana highlights the goals of a recently paused Department of Defense grant investigating treatment-resistant prostate cancer—and the consequences of further inaction.